Travere Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $62,898 | $54,116 | $41,374 | $45,059 |
Gross Profit | 50,033 | 41,710 | 39,870 | 28,643 |
EBITDA | -54,752 | -56,706 | -122,828 | -70,987 |
EBIT | -65,994 | -67,051 | -132,708 | -82,839 |
Net Income | -54,811 | -70,409 | -136,061 | -90,173 |
Net Change In Cash | 62,898 | 54,116 | 41,374 | 45,059 |
Free Cash Flow | -23,768 | -52,236 | -125,471 | -76,003 |
Cash | 36,409 | 32,290 | 43,251 | 58,176 |
Basic Shares | 77,779 | 77,500 | 77,136 | 76,474 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $145,238 | $212,018 | $227,490 | $198,321 |
Gross Profit | 88,856 | 204,426 | 220,706 | 192,195 |
EBITDA | -331,812 | -244,310 | -137,281 | -68,954 |
EBIT | -370,342 | -265,029 | -163,898 | -94,742 |
Net Income | -111,399 | -278,482 | -180,091 | -169,431 |
Net Change In Cash | 145,238 | 212,018 | 227,490 | 198,321 |
Cost of Revenue | -101,271 | 79,268 | 23,643 | |
Free Cash Flow | -322,280 | -214,848 | -38,943 | -162,588 |
Cash | 58,176 | 61,688 | 165,753 | 84,772 |
Basic Shares | 74,267 | 63,758 | 59,832 | 47,539 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.70 |
2024-06-30 | -$0.91 |
2024-03-31 | -$1.76 |
2023-12-31 | -$1.18 |
